Abstract Library

#4668 Predictive factors of postoperative recurrence in patients with neuroendocrine tumour of the lung: Prospective analysis of clinicopathologic features and radiomics

Introduction: In localised and locally advanced forms neuroendocrine tumours (NETs) of the lung radical surgical resection represents the standard of care, several clinicopathologic factors are potentially associated with recurrence of disease.

Conference:

Presenting Author: Paravani P

Authors: Paravani P, Russo F, Mazzilli R, Zamponi V, Mancini C,

Keywords: radiomics, predictive role, rfs, lung, lung net,

#4652 Clinical response to somatostatin analogues in patients with DIPNECH: Findings from a new longitudinal registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) often presents with symptoms of cough and dyspnoea. DIPNECH remains understudied, and response to somatostatin analogues (SSAs) has been reported in a few small series.

Conference:

Presenting Author: Libre M

Authors: Libre M, Skotte E, Linden A, Wu J, Lippincott E,

Keywords: DIPNECH, somatostatin analogue,

#4642 Establishing a standardised histopathological grading system for mesenteric fibrosis in small intestinal neuroendocrine tumours

Introduction: Mesenteric fibrosis (MF) frequently develops around mesenteric metastasis in small intestinal neuroendocrine tumour (SI-NET) patients. Since MF is not always detected radiologically, histopathological examination is considered the gold standard. However, there is no uniform histopathological scoring system for MF correlated with clinical data.

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, Hofland L, Hall A, Iyer A,

Keywords: small intestinal neuroendocrine tumour, mesenteric fibrosis, grading system,

#4616 Clinical characterisation of patients with familial midgut neuroendocrine tumours (FM-NETs) based on a comparison with the large population-based GTE/RENATEN cohort

Introduction: The clinical specificities of FM-NET have been poorly described.

Conference:

Presenting Author: Hunaut T

Authors: Hunaut T, Hercent A, Walter T, Buecher B, Lepage C,

Keywords: Small intestine neuroendocrine tumour, Familial carcinoid tumour,

#4591 Efficacy of Trabectedin and Olaparib in homologous repair deficient neuroendocrine neoplasms – A subgroup analysis of the TOP-ART / PMO-1603 trial

Introduction: Genomic alterations resulting in homologous recombination deficiency (HRD) occur in a variety of cancers including neuroendocrine neoplasms (NEN). HRD-positive tumours are sensitive to PARP inhibitors such as olaparib. The DNA minor groove binder trabectedin leads to DNA double strand breaks and PARP activation. The combination of Trabectedin + Olaparib (TrO) may therefore have synergistic effects in HRD-positive tumours.

Conference:

Presenting Author: Apostolidis L

Authors: Apostolidis L, Ruebsam M, Teleanu M, Wagner S, Dorman K,

Keywords: Neuroendocrine Tumour, Neuroendocrine Carcinoma, targeted therapy, chemotherapy, HRD, olaparib, trabectedin, net, nec,